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Potent antiretroviral therapy (ART) has dramatically improved the prognosis of HIV-1-infected individ-
uals. However, 10% to 30% of patients in Western countries still present late for care, when CD4 T cells
are below 200 cells/mm3 and symptomatic HIV disease has occurred. Clinical considerations for
advanced HIV disease are paramount as morbidity and mortality are directly correlated with a low
initial CD4 T cell count, which is commonly associated with the simultaneous occurrence of co-mor-
bidities, particularly opportunistic infections. Upon start of ART, the clinical entity of immune reconsti-
tution inflammatory syndrome may occur and, in this context, raise the question of early versus
delayed ART in patients treated for opportunistic infections. Recent data clearly indicate that an earlier
start of ART is warranted in this latter situation. Guidelines for specific antiretroviral treatment for late-
presenting patients are lacking. Knowledge about drug–drug interactions and co-morbidities should
guide treatment choices and influence the clinical management and monitoring of drug-related side
effects and interactions. Importantly, the outlook of patients who present late is very much dependent
upon the initial response to ART. Nevertheless, even if optimal response to treatment has been
achieved, long-term prognosis may be impaired in patients who initially presented with advanced HIV
disease. We encourage physicians to perform HIV testing more frequently in order to detect HIV-
infected individuals in time.
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Introduction
Combination antiretroviral therapy (ART) has dramatically
improved the prognosis of HIV-1 infected individuals.1 – 3
However, 10% to 30% of patients still present late for care,
when severe immunosuppression has already developed.
The natural course of HIV-1 infection is characterized by a
progressive loss of CD4 T cells leading to severe immunodefi-
ciency. A decrease in CD4 T cells below 200 cells/mm3 is the
threshold where the risk of opportunistic infections dramatically
increases. Therefore, current management of HIV infection aims
to prevent opportunistic infections and to reduce mortality by
starting ART before CD4 T cells decline below this critical
level.4 The advent of dual ART resulted in a decrease in mor-
tality of 30% to 50% in the early 1990s (Table 1),5 – 7 followed
by an even more dramatic improvement of prognosis with the
introduction of triple combination ART in the mid-1990s.1,7 – 12
However, HIV-infected patients continue to die from both
HIV-related and non-HIV-related causes. The residual morbidity
and mortality in HIV-infected patients are mainly due to the fol-
lowing reasons: (i) late presentation for HIV care with delayed
uptake of ART;13 (ii) age-related and CD4-independent morbid-
ity due to concomitant diseases (in particular cardiovascular
diseases, hepatitis C with liver failure, and malignancies);14,15
and (iii) suboptimal treatment because of multidrug-resistant
viral strains and lack of treatment options.16 Although the first
two factors are the predominant causes of death in HIV-infected
individuals, the prevalence of HIV resistance to all currently
available drug classes has recently decreased, reflecting the
important advances in this field. Owing to the development of
new drugs and drug classes, 50% to 70% of patients with highly
resistant HIV and triple class failure achieve optimal response to
ART with virological suppression below the limit of detection
(HIV-RNA ,50 copies/mL)17,18 and immunological recovery.
Scale of late presentation
Late and very late presentation of HIV-infected individuals may
be defined if CD4 T cell count at presentation for care is below
200 and 50 cells/mm3, respectively, or if an AIDS-defining con-
dition has already occurred. However, these definitions may shift
as more recent guidelines have recommended an earlier start of
therapy, i.e. once CD4 T cells drop below 350 cells/mm3.4
Moreover, there is increasing evidence that initiation of ART at
a higher CD4 T cell count of between 350 and 500 cells/mm3
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may be associated with a better prognosis of both HIV and
non-HIV-related conditions such as viral hepatitis C and malig-
nancies.4 Thus, late presentation might strongly affect overall
prognosis of HIV-infected individuals.
In the Western world, 10% to 30% of HIV-infected individ-
uals are reported to present late for care.13,19 This proportion is
clearly higher in developing countries, particularly in
sub-Saharan Africa, South-East Asia and South America,
because of the limited access to healthcare and HIV treat-
ment.20,21 Impressively, the median CD4 T cell count at starting
ART across all regions worldwide except Australia was reported
to be below 200 CD4 T cells/mm3 in the years 2003–05.22 The
clinical significance of late presentation was also examined in a
large cohort study in Switzerland, where 30% and 10% of
patients attended clinical care late and very late (i.e. with CD4 T
cells ,200 and ,50 cells/mm3), respectively.23 In this study,
late initiation of ART was predominantly due to late presentation
and not to delayed uptake of ART, as patients entering the Swiss
HIV Cohort Study promptly started ART. Risk factors of late
presentation were older age, heterosexual HIV transmission risk
and non-white ethnicity, similar to previous studies.13,24
In view of the marked differences in mortality when compar-
ing late presenting individuals with those presenting earlier, and
the prolonged risk of HIV transmission, prevention of late pres-
entation by expanded HIV-testing and reduction of organiz-
ational, psychosocial and educational barriers is a priority.
Clinical considerations for advanced disease
Clinical considerations and evaluation of late-presenting
HIV-infected individuals and advanced HIV disease include
history of previous opportunistic infections, HIV-associated
symptoms, for example, weight loss, diarrhoea, fatigue and con-
comitant diseases (particularly co-infection with viral hepatitis
B and/or C; psychiatric disorders and active substance abuse),
which could complicate ART or negatively influence adherence
to ART. In the physical examination, subtle clinical signs might
give an indication of mild-to-moderate immunodeficiency, e.g.
oral candidiasis or oral hairy leukoplakia; for further details,
see review by Battegay et al.25 More importantly, the diagnostic
approach in a patient recently starting ART who develops new
symptoms is very challenging. E.g. fever, in particular low-grade
fever, might be due to: (i) HIV directly (very high viral loads);
(ii) HIV-related complications such as opportunistic infections;
(iii) immune reconstitution inflammatory syndrome (IRIS) after
initiation of ART; (iv) drug-related complications (through treat-
ment of opportunistic infections or ART); (v) concurrent unre-
lated complications, for example, catheter-related infections; or
(vi) other diseases.
In addition to symptoms and signs of advanced HIV disease,
late presentation has particular features in conjunction with IRIS
after the initiation of ART. Figure 1 illustrates the possible
pathophysiology of IRIS.26 – 28 Fever and enlarged lymph nodes
are typical clinical signs of excessive inflammatory response.
Importantly, such specific reactions are crucial for the
Figure 1. Advanced HIV disease with low CD4 T cells count and high
pathogen endemicity are well-known risk factors for IRIS. Due to very low
CD4 T cell counts, CD4- and/or CD8-mediated cellular immune responses
are likely to be strongly impaired and defence inflammatory reactions may
not develop. Consequently, the threshold for clinically manifested disease is
not crossed. Following ART initiation, viral load rapidly decreases and
cellular immune functions improve within days or weeks, leading to an
increased pathogen-specific immunity, which becomes apparent as an
inflammatory reaction. Of course, such a reaction is recognizable only if a
pathogen is present.
Table 1. ART dramatically decreased mortality
Year Study Design Decrease in mortality (%)
1997 Delta5 RCT ZDV versus dual ART 30–50
1997 ACTG 1757 RCT ZDV versus dual ART 30–50
1997 ACTG 3208 RCT dual versus HAART 70–80
1997 SHCS1 OS no HAART versus HAART 70–80
1998 HOPS9 OS no HAART versus HAART 70–80
2003 EUROSIDA10 OS 1996–97 HAART versus 1998–2002 HAART 86
2005 SHCS11 OS no HAART versus HAART 86
2007 Danish cohort12 OS HIV versus non-HIV 10–38 years of life
prolongation after start of ART
normal life expectancy (?)
RCT, randomized controlled trial; OS, observational study; ZDV, zidovudine; HAART, highly active antiretroviral therapy.
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elimination of opportunistic infections, and later for stopping
primary or secondary prophylaxis for such pathogens. However,
in rare cases, IRIS may lead to severe complications including
death. Importantly, data from recent studies clearly indicate that
early combination ART is advantageous when opportunistic
infections are present, as the overall mortality is excessively
high in patients presenting with very late HIV disease and
opportunistic infections.27 – 29 It has been shown that delaying
combination ART is associated with increased mortality.29 Also,
IRIS can be managed with close monitoring and symptomatic
treatment including steroids.29,30 Management of late presenters
with tuberculosis is particularly challenging because of the high
risk of developing IRIS, estimated at up to 32% in association
with low CD4 T cell count at baseline and early ART initiation,30
additive drug toxicity and interactions resulting from antimyco-
bacterial therapy. In case of active tuberculosis at presentation,
immediate antituberculous treatment should be started and ART
should not be postponed by more than 4–8 weeks. However,
ART may be initiated even earlier if the CD4 T cell count is very
low (,50 cells/mm3) as HIV-related mortality is very high in this
circumstance. If reactivation of tuberculosis becomes clinically
apparent during ART (i.e. IRIS), it is possible to continue ART
because IRIS is usually not life-threatening.30
ART for late presenters
Is there a specific initial ART regimen for late presenters? The
simplest answer would be no. However, several aspects which
also apply for the earlier initiation of treatment should be con-
sidered before starting ART in late presenters. First, the presence
of transmitted HIV drug resistance, which may occur in 5% to
25% of patients and predominantly refers to non-nucleoside
reverse transcriptase inhibitors (NNRTIs),31 should be investi-
gated. Secondly, factors that may influence clinical management
and require close monitoring of drug-related side effects and drug
interactions, such as co-infection with viral hepatitis B and/or C
and concomitant treatment of opportunistic infections, should be
evaluated. Thirdly, the presence of psychiatric disorders, active
drug use or socioeconomic barriers, which may negatively affect
adherence and therefore efficacy of treatment, should be assessed.
The question of whether boosted protease inhibitors (PIs) or
NNRTIs should be chosen as a third drug is also difficult to
answer. A large meta-analysis of 53 trials including 14 264
patients indicated that these two drug classes are of equitable
potency, as measured by the percentage of virological suppres-
sion (HIV-RNA below 50 copies/mL) achieved at 48 weeks
after starting treatment.32 Similarly, no difference in the
immunological response and the rate of clinical progression was
observed among patients receiving a PI or NNRTI in the initial
ART regimen. Nevertheless, an observational study suggests that
patients receiving PI develop drug resistance less frequently
following virological failure.31 In conclusion, both NNRTI- and
boosted PI-based ART have similar first-line potency, but a PI
might be advantageous in particular clinical situations due to the
particularly favourable resistance profile, allowing preservation
of more future drug options. Similarly, no specific guidelines
exist for the choice of backbone ART, i.e. nucleoside reverse
transcriptase inhibitors (NRTI), in late presenters. However,
tenofovir, when used in conjunction with didanosine and zidovu-
dine, has tended to be associated with lower CD4 T cell
increases in recent studies.33 – 35 The clinical significance of sub-
optimal initial CD4 T cell increase remains unclear. Although
late presentation with low baseline CD4 T cell count is the
strongest prognostic factor for early mortality in both low and
high income countries,19 data from a large cohort study suggest
that even patients starting ART with very low CD4 T cell counts
show sustained significant immunological recovery over 5 years
of ART.36 The majority of very late presenters with severe
opportunistic infections will survive due to the availability of
very potent antiretroviral drugs.
In conclusion, late presentation is associated with a poorer
short-term outcome as well as possibly worse long-term progno-
sis. Recent advances in HIV treatment make this issue more
urgent. It is important to state that care and management of late
presenters have shown impressive progress. Among these
advances, the understanding and better management of late pres-
entation in conjunction with opportunistic infections, the hand-
ling of side effects and drug–drug interactions, the management
of severe infections such as Pneumocystis jirovecii pneumonia
and/or tuberculosis have clearly improved survival of these
patients. Nevertheless, appropriate management of late presen-
tation with severe advanced HIV disease is critical. Prognosis
depends much upon the expertise and knowledge of HIV
experts, internists and, if needed, intensive care specialists. In
view of the public health implications of early HIV diagnosis
for reducing HIV transmission and preventing late presentation,
HIV testing should be more frequently recommended in all
healthcare settings. HIV screening is currently recommended for
all pregnant women, and at least annually for persons at high risk
of HIV infection.37 It is to be hoped that in the future the clinical
entity of late presentation will become significantly rarer.
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